Frontlight ResearchEarly access
Taking people in United StatesPhase 2
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Cincinnati, Portland, and Salt Lake City, United StatesSee the 3 sitesAlso in 7 other countries, 19 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 3 Nov 2025
- Expected to end
- 17 May 2028
- Type of study
- Interventional
- Treatments tested
- MAS825
- Record updated
- 9 November 2026
Who can take part
- Age
- 1 year and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age ≥ 1 with a diagnosis of Still's Disease
- Active diseases defined as:
- CRP or ferritin levels greater than ULN, and any of:; Fever ≥ 38°C attributed to Still's Disease activity and documented for a number of days prior to Day 1 or; Rash attributed to Still's Disease activity or; Musculoskeletal involvement: arthritis in a number of joints per ACP criteria for active joint or; Serositis or; Macrophage activation syndrome activity as defined by ferritin levels and at least one of: platelet count, a biomarker or fibrinogen levels attributed to Still's Disease activity by the investigator
- Intolerance or inadequate response to available biologic therapy
Who cannot take part
- Ongoing or previous treatment with immunomodulatory drugs; A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study
- Live vaccinations within a set time prior to MAS825 treatment. Live vaccines are prohibited up to several months following the last dose
- Any conditions or significant medical problems which places the patient at unacceptable risk for MAS825 therapy; Still's disease patients with evidence of macrophage activation syndrome are permitted in the study; Still's Disease patients with evidence of interstitial lung disease including those requiring supplemental oxygen therapy are permitted in the study
- History of ongoing, chronic or possibly recurrent infection (e.g. HIV, TB, HCV, HBV) and/or symptoms and signs of clinically significant active bacterial, fungal or viral infections
- History of malignancy of any organ system, including post-transplant lymphoproliferative disorder, treated or untreated, within a number of years, regardless of whether there is evidence of local recurrence and metastases
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or to any of the excipients
- Patients out of weight range
- Glucocorticoid dose exceeding a set limit
- Pregnant or breastfeeding women
- Women of child-bearing potential who do not agree to comply with required contraceptive use; Other protocol-defined inclusion/exclusion criteria may apply
Where in United States
Also in 7 other countries, 19 sites
- Cincinnati Childrens HospitalCincinnati, United StatesContact: Novartis PharmaceuticalsNo longer taking part
- Legacy Emanuel Research Hosp PortlandPortland, United StatesContact: Brenna BogleTaking people
- University of UtahSalt Lake City, United StatesContact: Tressie RollinsTaking people
About the trial
What the trial wants to find out
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
The group in the trial
- MAS825Treatment being tested
Experimental drug
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
- Record updated
- 9 November 2026